I'm LongbridgeAI, I can summarize articles.Johnson & Johnson (JNJ.US) hit a record high in overnight trading, last at $288.42, after rising less than 1% during the regular session.
The stock is up 5.56% over the past ten sessions and up 41.60% year to date. It sits 52.46% above its 52-week low of US$189.18.
The Nasdaq Composite is up 2.27% over the past five sessions and up 8.15% year to date.
According to the Financial Times, the company is in talks to acquire private ophthalmology biotech Ollin Biosciences for up to $3.4 billion. The deal structure includes $2.2 billion in upfront cash and up to $1.2 billion in potential milestone payments, though negotiations could still fall apart.
Separately, Janssen China announced on Nov. 14 that new indications for its drugs Rybrevant and Darzalex Faspro have been included in the 2026 National Reimbursement Drug List, covering generalized myasthenia gravis and multiple myeloma. Meanwhile, Caplyta met primary and key secondary endpoints in a second pivotal Phase 3 trial for bipolar I disorder mania, with plans to file for regulatory approval in the U.S.
Based on public media reports. AI-generated; not investment advice.
